A Phase II Placebo-Controlled Trial of Neoadjuvant Anastrozole Alone or With Gefitinib in Early Breast Cancer
Ian E. Smith(Papworth Hospital), Mitch Dowsett(Institute of Cancer Research), Antonio Llombart‐Cussac(MedSIR (Spain)), Emma Clark(Royal Bournemouth Hospital), Patrick Magill(Royal Bournemouth Hospital), Geraldine Walsh(Royal Marsden NHS Foundation Trust), Janine Salter(Nottingham City Hospital), Simone Detre(Royal Bournemouth Hospital), Anthony Skene(Royal Bournemouth Hospital), José Mayordomo(Royal Bournemouth Hospital)
Cited by 203
Related Papers
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
|Annals of Oncology|2001|714
Mechanisms of tamoxifen resistance
|Endocrine Related Cancer|2004|652